Developer docs
API playgroundTry for free, no card

Search company profiles

Oxford Immune Algorithmics

Full company profile

uuid0002pen

Namestring
Oxford Immune Algorithmics
Legal namestring
Oxford Immune Algorithmics Ltd.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Oxford Immune Algorithmics (OIA) is a UK-based medical device company developing the Algocyte platform for at-home blood diagnostics. Its flagship product, Algocyte Proxima, is a CE-marked dual-sensor hematological analyser that converts physical sensor signals into blood test results in minutes, replacing the conventional clinical-visit-and-lab model. The device is paired with the Algocyte Health Hub companion app (Bluetooth-controlled) and single-use, cold-chain-free CE-marked cartridges. Underlying the device is a patented physics-informed AI architecture, described as quantum mechanics-inspired and anchored in physics and biology rather than pure data-driven methods, with US Patents 11175230 and 11534751 protecting the approach. The company was incubated at Oxford University and spun out from King's College London, with clinical leadership rooted in NHS and Cambridge ecosystems.

The company targets five primary customer segments: (1) healthcare providers and NHS hospital-at-home programs seeking decentralized monitoring, (2) oncology pathways requiring regular full blood count monitoring for treatment continuity, (3) community psychiatry services requiring clozapine patient monitoring, (4) domiciliary and care home providers, and (5) individual consumers and families seeking personal health intelligence. Secondary segments include payors (value-based care outcome data) and pharmaceutical companies (decentralized clinical trials). The revenue model is a hardware-plus-consumables-plus-subscription architecture: device sales, recurring single-use cartridge revenue, and ongoing app/dashboard subscription services.

OIA's go-to-market combines enterprise field sales to healthcare providers and NHS trusts, event-driven demand generation (including a flagship Royal Society of Medicine launch on June 29, 2026), direct-to-consumer self-serve distribution through the Health Hub app, and a content-led awareness strategy. The company holds ISO 13485, ISO/IEC 27001:2022, Cyber Essentials Plus, and UKCA certifications, and is an Official NHS Partner (featured in the NHS 75th Anniversary book). Approximately $7.13 million has been raised across two 2021 funding rounds; no subsequent financing or commercial revenue is publicly disclosed. The Health Hub's future release will introduce baseline learning and trend analysis against a dataset of 120M+ aggregated blood test results to support differential diagnosis, expanding the platform beyond diagnostic hardware into longitudinal health intelligence.

Short descriptiontext

Oxford Immune Algorithmics develops the Algocyte Proxima, a CE-marked at-home dual-sensor hematological analyser using patented physics-informed AI to deliver blood test results in minutes. It serves NHS providers, oncology and clozapine clinics, payors, pharma, and consumers via a hardware-plus-consumables-plus-subscription model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReading, United Kingdom
HQ citystring
Reading
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
at-home blood testing, physics-informed AI diagnostics, haematological analyser devices, decentralized healthcare monitoring, medical diagnostics cartridges
Industry2 codes
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Medical Diagnostics
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hardware Device Sales
TypeHardware Sales
Description

Sale of the Algocyte Proxima device - a hardware medical device for at-home blood testing.

algocyte.ai
2Consumables (Test Kits/Cartridges)
TypeUsage Based
Description

Single-use CE-marked cartridges required for each test. Recurring consumable revenue tied to testing frequency.

algocyte.ai
3Subscription Services
TypeSubscription Recurring
Description

Ongoing subscription for app access, data analysis, trend monitoring, and clinical dashboard services.

algocyte.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Algocyte Proxima
Description

The main at-home blood testing device and system featuring dual-sensor haematological analyser technology.

algocyte.ai
+2 more records
Core offering1 text field

Oxford Immune Algorithmics (Algocyte) sells the Algocyte Proxima dual-sensor haematological analyser device and its surrounding ecosystem—an at-home blood-testing platform that uses physics-informed AI to convert physical sensor signals into blood-test results delivered in minutes, paired with single-use CE-marked cartridges, a Bluetooth-connected companion mobile app (Health Hub), and a Clinician Dashboard with EHR integration capability. The offering targets healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers/families for regular decentralized immune monitoring.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Oxford Immune Algorithmics offers Algocyte Proxima, a unified platform-plus-ecosystem architecture for at-home blood testing. The core product is the Algocyte Proxima dual-sensor haematological analyser, which pairs with the Algocyte Health Hub companion app (controlling the device via Bluetooth) and single-use CE-marked cartridges. Results are delivered to both the patient's phone app and the clinician's dashboard. The platform targets multiple care pathways including hospital-at-home, oncology, clozapine monitoring, and domiciliary care, with future capabilities for preventive and longevity health monitoring.

Product and service4 records
1Algocyte Proxima™
CategoryMedical Device / Diagnostic Hardware
Description

Dual-sensor haematological analyser device that brings blood testing into the home. Uses physics-informed AI to convert physical sensor signals into analyte measurements, with results delivered in minutes to a companion app and clinician dashboard. For healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers.

2Algocyte Health Hub (Companion App)
CategorySoftware / Mobile Health Application
Description

Mobile companion application that guides users through each test, controls the Algocyte Proxima device via Bluetooth, receives results, and shares them with clinicians. A future release will learn user baseline and analyse trends against aggregated blood test data for differential diagnosis. For individual consumers and clinicians.

3Single-Use CE-Marked Cartridges (Test Kits)
CategoryMedical Consumables
Description

Single-use test cartridges that require no cold chain storage, designed for plug-and-play operation with the Algocyte Proxima device. Recurring consumable revenue tied to testing frequency. For users of the Algocyte Proxima system.

4Clinician Dashboard
CategoryClinical Software Platform
Description

Web-based dashboard for clinicians to receive and review patient test results in minutes, with EHR integration capability for oncology pathways, online/offline sharing, and interpretation guidance. For healthcare providers and clinicians.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Official partner of the NHS, featured on the NHS 75th anniversary book. The company has clinical leadership and research rooted in the NHS ecosystem, with the technology designed to support NHS care pathways and decentralized care models.

2Future Blood Testing Network+
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key partner in the UK's EPSRC research network awarded a grant to explore the future of blood testing. This partnership provides research validation and academic credibility for the company's technology.

algocyte.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Oxford Immune Algorithmics spun out from King's College London, indicating deep research collaboration and technology transfer from this academic institution.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Company was incubated at Oxford University, indicating research collaboration and technology development originating from this institution.

5Cambridge Ecosystem
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical leadership and research rooted in the Cambridge ecosystem, indicating secondary academic partnership for research and talent.

algocyte.ai
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Cue Health
TypeDirect peer
Description

Cue Health built a connected at-home molecular diagnostics platform with a hardware reader, single-use cartridges, and a companion app delivering lab-grade results in minutes. It is the closest functional analog to Algocyte Proxima's hardware-plus-AI-plus-app architecture for decentralized testing.

TypeDirect peer
Description

Tasso develops virtually painless at-home blood collection devices used in decentralized clinical trials and remote patient monitoring. It competes directly with OIA for home-based blood sampling workflows, particularly in pharma-sponsored DCT and oncology monitoring use cases.

TypeDirect peer
Description

LetsGetChecked offers a DTC and B2B home diagnostics platform combining self-collected samples, CE/FDA-regulated tests, and clinician-reviewed results. It competes with the consumer/employer side of Algocyte's value proposition and shares the recurring-testing business model.

TypeDirect peer
Description

Thriva is a UK-based home blood testing service offering subscription-based finger-prick panels with clinician review and trend tracking. It is the most direct UK geographic peer, sharing OIA's focus on regular at-home blood monitoring for preventive and chronic care.

TypeDirect peer
Description

Everlywell sells a broad menu of at-home diagnostic tests (including full blood count panels) directly to consumers and through enterprise channels. It overlaps with OIA on consumer-facing home blood testing and recurring panel subscriptions.

TypeDirect peer
Description

Healthy.io turns smartphone cameras into clinical-grade urinalysis and wound-care diagnostics, with NHS and US health plan distribution. It shares OIA's strategy of converting consumer hardware into regulated diagnostic tools embedded in healthcare pathways.

TypeEmerging player
Description

Yourbio Health developed the Tap device for virtually painless capillary blood collection, used in remote clinical trials and women's health. It overlaps with OIA on enabling remote blood sampling, though it focuses on collection rather than in-home analysis.

TypeBroad incumbent
Description

iRhythm's Zio long-term cardiac monitor combines a wearable biosensor, an AI-based detection algorithm, and a clinician reporting service. It is an incumbent analog in the at-home biosensor-plus-AI diagnostic category, targeting continuous remote monitoring for cardiology.

TypeBroad incumbent
Description

Labcorp's consumer and employer-facing services (Pixel, OnDemand) sell self-collected blood panels with lab-processed results. It represents the incumbent central-lab workflow OIA is trying to displace with at-home point-of-care hematology.

TypeBroad incumbent
Description

Siemens Healthineers manufactures point-of-care blood analyzers (epoc blood gas, DCA analyzers for HbA1c) widely used in hospital and near-patient settings. It is the broader incumbent in connected hematology / clinical-chemistry point-of-care devices that OIA is miniaturizing for the home.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oxford Immune Algorithmics

Medical Diagnosticsimmunealgorithmics.com

Oxford Immune Algorithmics develops the Algocyte Proxima, a CE-marked at-home dual-sensor hematological analyser using patented physics-informed AI to deliver blood test results in minutes. It serves NHS providers, oncology and clozapine clinics, payors, pharma, and consumers via a hardware-plus-consumables-plus-subscription model.

What Oxford Immune Algorithmics does

Oxford Immune Algorithmics (OIA) is a UK-based medical device company developing the Algocyte platform for at-home blood diagnostics. Its flagship product, Algocyte Proxima, is a CE-marked dual-sensor hematological analyser that converts physical sensor signals into blood test results in minutes, replacing the conventional clinical-visit-and-lab model. The device is paired with the Algocyte Health Hub companion app (Bluetooth-controlled) and single-use, cold-chain-free CE-marked cartridges. Underlying the device is a patented physics-informed AI architecture, described as quantum mechanics-inspired and anchored in physics and biology rather than pure data-driven methods, with US Patents 11175230 and 11534751 protecting the approach. The company was incubated at Oxford University and spun out from King's College London, with clinical leadership rooted in NHS and Cambridge ecosystems.

The company targets five primary customer segments: (1) healthcare providers and NHS hospital-at-home programs seeking decentralized monitoring, (2) oncology pathways requiring regular full blood count monitoring for treatment continuity, (3) community psychiatry services requiring clozapine patient monitoring, (4) domiciliary and care home providers, and (5) individual consumers and families seeking personal health intelligence. Secondary segments include payors (value-based care outcome data) and pharmaceutical companies (decentralized clinical trials). The revenue model is a hardware-plus-consumables-plus-subscription architecture: device sales, recurring single-use cartridge revenue, and ongoing app/dashboard subscription services.

OIA's go-to-market combines enterprise field sales to healthcare providers and NHS trusts, event-driven demand generation (including a flagship Royal Society of Medicine launch on June 29, 2026), direct-to-consumer self-serve distribution through the Health Hub app, and a content-led awareness strategy. The company holds ISO 13485, ISO/IEC 27001:2022, Cyber Essentials Plus, and UKCA certifications, and is an Official NHS Partner (featured in the NHS 75th Anniversary book). Approximately $7.13 million has been raised across two 2021 funding rounds; no subsequent financing or commercial revenue is publicly disclosed. The Health Hub's future release will introduce baseline learning and trend analysis against a dataset of 120M+ aggregated blood test results to support differential diagnosis, expanding the platform beyond diagnostic hardware into longitudinal health intelligence.

Oxford Immune Algorithmics firmographics

Firmographics
Name
Oxford Immune Algorithmics
Legal name
Oxford Immune Algorithmics Ltd.
Website
https://immunealgorithmics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Oxford Immune Algorithmics develops the Algocyte Proxima, a CE-marked at-home dual-sensor hematological analyser using patented physics-informed AI to deliver blood test results in minutes. It serves NHS providers, oncology and clozapine clinics, payors, pharma, and consumers via a hardware-plus-consumables-plus-subscription model.
Ownership category
akta.pro rank

Oxford Immune Algorithmics industry classification

Industry
Product category
Medical Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • At-home blood testing
  • Physics-informed AI diagnostics
  • Haematological analyser devices
  • Decentralized healthcare monitoring
  • Medical diagnostics cartridges

Where Oxford Immune Algorithmics is headquartered

Location

Headquarters

HQ city
Reading
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Oxford Immune Algorithmics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Hardware Device Sales: Sale of the Algocyte Proxima device - a hardware medical device for at-home blood testing.
  2. Consumables (Test Kits/Cartridges): Single-use CE-marked cartridges required for each test. Recurring consumable revenue tied to testing frequency.
  3. Subscription Services: Ongoing subscription for app access, data analysis, trend monitoring, and clinical dashboard services.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Oxford Immune Algorithmics product offering

Product offering

Core offering

Oxford Immune Algorithmics (Algocyte) sells the Algocyte Proxima dual-sensor haematological analyser device and its surrounding ecosystem—an at-home blood-testing platform that uses physics-informed AI to convert physical sensor signals into blood-test results delivered in minutes, paired with single-use CE-marked cartridges, a Bluetooth-connected companion mobile app (Health Hub), and a Clinician Dashboard with EHR integration capability. The offering targets healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers/families for regular decentralized immune monitoring.

Product overview

Oxford Immune Algorithmics offers Algocyte Proxima, a unified platform-plus-ecosystem architecture for at-home blood testing. The core product is the Algocyte Proxima dual-sensor haematological analyser, which pairs with the Algocyte Health Hub companion app (controlling the device via Bluetooth) and single-use CE-marked cartridges. Results are delivered to both the patient's phone app and the clinician's dashboard. The platform targets multiple care pathways including hospital-at-home, oncology, clozapine monitoring, and domiciliary care, with future capabilities for preventive and longevity health monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • Algocyte Proxima: The main at-home blood testing device and system featuring dual-sensor haematological analyser technology.
  • Algocyte Health Hub
  • Algocyte Test Hub

Products and services

  • Algocyte Proxima™ Dual-sensor haematological analyser device that brings blood testing into the home. Uses physics-informed AI to convert physical sensor signals into analyte measurements, with results delivered in minutes to a companion app and clinician dashboard. For healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers.
  • Algocyte Health Hub (Companion App) Mobile companion application that guides users through each test, controls the Algocyte Proxima device via Bluetooth, receives results, and shares them with clinicians. A future release will learn user baseline and analyse trends against aggregated blood test data for differential diagnosis. For individual consumers and clinicians.
  • Single-Use CE-Marked Cartridges (Test Kits) Single-use test cartridges that require no cold chain storage, designed for plug-and-play operation with the Algocyte Proxima device. Recurring consumable revenue tied to testing frequency. For users of the Algocyte Proxima system.
  • Clinician Dashboard Web-based dashboard for clinicians to receive and review patient test results in minutes, with EHR integration capability for oncology pathways, online/offline sharing, and interpretation guidance. For healthcare providers and clinicians.

Companies that use Oxford Immune Algorithmics

Customer profile

Segments7 records

Ideal customer profiles6 records

Oxford Immune Algorithmics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

Oxford Immune Algorithmics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • National Health Service (NHS)coreStrategic or Co-development Partner · 1 January 2024Official partner of the NHS, featured on the NHS 75th anniversary book. The company has clinical leadership and research rooted in the NHS ecosystem, with the technology designed to support NHS care pathways and decentralized care models.
  • Future Blood Testing Network+coreStrategic or Co-development PartnerKey partner in the UK's EPSRC research network awarded a grant to explore the future of blood testing. This partnership provides research validation and academic credibility for the company's technology.
  • King's College LondoncoreStrategic or Co-development PartnerOxford Immune Algorithmics spun out from King's College London, indicating deep research collaboration and technology transfer from this academic institution.
  • Oxford UniversitycoreStrategic or Co-development PartnerCompany was incubated at Oxford University, indicating research collaboration and technology development originating from this institution.
  • Cambridge EcosystemminorStrategic or Co-development PartnerClinical leadership and research rooted in the Cambridge ecosystem, indicating secondary academic partnership for research and talent.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Oxford Immune Algorithmics competitors and assessment

Company assessment

Direct peers

  • Cue Health: Cue Health built a connected at-home molecular diagnostics platform with a hardware reader, single-use cartridges, and a companion app delivering lab-grade results in minutes. It is the closest functional analog to Algocyte Proxima's hardware-plus-AI-plus-app architecture for decentralized testing.
  • Tasso: Tasso develops virtually painless at-home blood collection devices used in decentralized clinical trials and remote patient monitoring. It competes directly with OIA for home-based blood sampling workflows, particularly in pharma-sponsored DCT and oncology monitoring use cases.
  • LetsGetChecked: LetsGetChecked offers a DTC and B2B home diagnostics platform combining self-collected samples, CE/FDA-regulated tests, and clinician-reviewed results. It competes with the consumer/employer side of Algocyte's value proposition and shares the recurring-testing business model.
  • Thriva: Thriva is a UK-based home blood testing service offering subscription-based finger-prick panels with clinician review and trend tracking. It is the most direct UK geographic peer, sharing OIA's focus on regular at-home blood monitoring for preventive and chronic care.
  • Everlywell: Everlywell sells a broad menu of at-home diagnostic tests (including full blood count panels) directly to consumers and through enterprise channels. It overlaps with OIA on consumer-facing home blood testing and recurring panel subscriptions.
  • Healthy.io: Healthy.io turns smartphone cameras into clinical-grade urinalysis and wound-care diagnostics, with NHS and US health plan distribution. It shares OIA's strategy of converting consumer hardware into regulated diagnostic tools embedded in healthcare pathways.

Emerging players

  • Yourbio Health: Yourbio Health developed the Tap device for virtually painless capillary blood collection, used in remote clinical trials and women's health. It overlaps with OIA on enabling remote blood sampling, though it focuses on collection rather than in-home analysis.

Broad incumbents

  • iRhythm Technologies: iRhythm's Zio long-term cardiac monitor combines a wearable biosensor, an AI-based detection algorithm, and a clinician reporting service. It is an incumbent analog in the at-home biosensor-plus-AI diagnostic category, targeting continuous remote monitoring for cardiology.
  • Labcorp OnDemand / Labcorp Pixel: Labcorp's consumer and employer-facing services (Pixel, OnDemand) sell self-collected blood panels with lab-processed results. It represents the incumbent central-lab workflow OIA is trying to displace with at-home point-of-care hematology.
  • Siemens Healthineers (epoc / DCA): Siemens Healthineers manufactures point-of-care blood analyzers (epoc blood gas, DCA analyzers for HbA1c) widely used in hospital and near-patient settings. It is the broader incumbent in connected hematology / clinical-chemistry point-of-care devices that OIA is miniaturizing for the home.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Oxford Immune Algorithmics social profiles

Digital presence

Oxford Immune Algorithmics compliance and trust

Trust signal

Compliance4 records

Oxford Immune Algorithmics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oxford Immune Algorithmics leadership team

Management profile

Number of profiles

Profiles5 records

Oxford Immune Algorithmics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oxford Immune Algorithmics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Immune Algorithmics

What does Oxford Immune Algorithmics do?

Oxford Immune Algorithmics (Algocyte) sells the Algocyte Proxima dual-sensor haematological analyser device and its surrounding ecosystem—an at-home blood-testing platform that uses physics-informed AI to convert physical sensor signals into blood-test results delivered in minutes, paired with single-use CE-marked cartridges, a Bluetooth-connected companion mobile app (Health Hub), and a Clinician Dashboard with EHR integration capability. The offering targets healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers/families for regular decentralized immune monitoring.

Is Oxford Immune Algorithmics a public or private company?

Oxford Immune Algorithmics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oxford Immune Algorithmics founded?

Oxford Immune Algorithmics was founded in 2018. It employs 11 to 50 people.

Where is Oxford Immune Algorithmics based?

Oxford Immune Algorithmics is headquartered in Reading, United Kingdom, in the Europe region.

How does Oxford Immune Algorithmics make money?

Three revenue lines are on record. Hardware Device Sales are the primary driver. The others are consumables (Test Kits/Cartridges) and subscription Services.

Who are Oxford Immune Algorithmics's main competitors?

Direct peers on record are Cue Health, Tasso, LetsGetChecked, Thriva, Everlywell and Healthy.io. Yourbio Health is listed as an emerging player. Broad incumbents are iRhythm Technologies, Labcorp OnDemand / Labcorp Pixel and Siemens Healthineers (epoc / DCA).

Does Oxford Immune Algorithmics have an API?

No public API is recorded for Oxford Immune Algorithmics.

What industry is Oxford Immune Algorithmics in?

Oxford Immune Algorithmics's product category is Medical Diagnostics. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 325413 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireQuantGate Systems Inc. Signs Collaboration Agreement with Oxford Immune Algorithmics (OIA), Welcomes AI Expert Dr. Hector Zenil to Advisory BoardQuantGate Systems Inc. signed a collaboration agreement with Oxford Immune Algorithmics to integrate AGI into its Pilot Trading product. AI expert Dr. Hector Zenil was appointed to QuantGate's advisory board. The partnership aims to deliver innovative fintech solutions powered by AGI.Tech.euOxford Immune Algorithmics develops personalised, predictive healthcareOxford Immune Algorithmics, a UK startup, developed Algocyte, an AI platform that integrates blood test data with patient records to monitor health and issue early warnings. The company also plans handheld devices for at-home blood tests, with the medical instrument launching next year. Founder Dr. Hector Zenil predicts adoption from consumers, insurers, and life science firms.GlobeNewswireWhere AI Meets Immunity: Oxford Immune Algorithmics to Launch Predictive Medicine SolutionOxford Immune Algorithmics will launch Algocyte, an AI-powered cloud-based predictive medicine platform using handheld devices for blood tests. The first product is a complete blood count test, aiming to speed diagnostics and reduce hospital visits. The company expects adoption to transform healthcare by expanding monitoring to healthy people.Digital Health Technology NewsMyGlobalHome partners with Oxford Immune Algorithmics to revolutionise healthcare in the homeMyGlobalHome partnered with Oxford Immune Algorithmics to integrate the AI medical assistant Algocyte into its digital health ecosystem. Algocyte enables remote blood tests and alerts users to up to 30 diseases, including leukaemia and sepsis, within two days. The company urges users to inform their GPs of results.BdailyMyGlobalHome partners with Oxford Immune Algorithmics to revolutionise healthcare in the homeMyGlobalHome partnered with Oxford Immune Algorithmics to integrate the Algocyte AI Medical Assistant into its digital health ecosystem. The integration enables remote personal blood tests and home access to results via a smart monitor, with users advised to inform their GPs. The partnership aims to advance telemedicine and home-based healthcare.